IRADIMED CORPORATIONIRMD stock score: 66/100
$81.26 · -1.28% · Scored Nov 19, 2026
- Technical
- 40
- Fundamental
- 72
- News
- 51
The reading
IRADIMED (IRMD) scores 66 out of 100, which reads bullish, higher than 91% of Healthcare stocks and 92% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 72, technicals 40.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Price to Book Ratio at 2 weighs the most against it.
On the daily chart, trend-following indicators average 25 and contrarian oscillators 61 — a split worth reading before trusting the technical total.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 54 to 68, and it is up 6 points over the period.
About IRADIMED
IRADIMED (IRMD) makes medical devices designed to work safely inside MRI suites, where strong magnetic fields rule out most standard equipment. Its main product line is the MRidium family of non-magnetic IV infusion pumps, which let clinicians keep delivering fluids and medications to patients during MRI scans. It also makes an MRI-compatible patient vital signs monitor and a ferrous metal detection system meant to help keep magnetic objects out of the scanner room. The company sells mainly to hospitals and acute care facilities, using its own sales force in the United States and distributors in other countries. It earns money from device sales, along with recurring sales of proprietary disposable infusion sets used with its pumps and from service. It has launched a next-generation infusion pump and is replacing older pumps in hospitals’ fleets.
IRADIMED faces few direct rivals in MRI-compatible pumps, though hospitals can instead run long tubing from standard pumps outside the scanner room. In MRI patient monitoring it competes with larger equipment makers such as Philips. Its edge rests on specialized engineering for magnetic environments, regulatory clearances and an installed base that drives disposable sales. Investors who follow IRMD stock tend to watch adoption and shipments of the new pump and the pace of upgrades across hospitals. Monitor and disposable sales are closely followed. Hospital capital budgets, the dividend and new products are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward IRMD’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
72Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Price-to-Book ratio compares market value to book value.
Price-to-Sales ratio compares market capitalization to annual revenue.
EV/EBITDA compares the whole company's value, debt included, with its operating earnings before depreciation.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
29Pulling it up
Williams %R (7-period) places the close within the last 7 periods' high-low range.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Holding it back
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Where the close sits against its 200-day SMA.
Combined Exponential Moving Average score aggregates multiple EMA periods into a single metric.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 37 | 1 |
| Daily | 29 | 3 |
| Weekly | 41 | 2 |
| Monthly | 58 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 66 |
| Nov 18, 2026 | 66 |
| Nov 17, 2026 | 66 |
| Nov 16, 2026 | 67 |
| Nov 15, 2026 | 67 |
| Nov 14, 2026 | 67 |
| Nov 13, 2026 | 68 |
| Nov 12, 2026 | 68 |
| Nov 11, 2026 | 62 |
| Nov 10, 2026 | 62 |
| Nov 8, 2026 | 61 |
| Nov 7, 2026 | 61 |
| Nov 6, 2026 | 61 |
| Nov 5, 2026 | 60 |
| Nov 4, 2026 | 62 |
| Nov 3, 2026 | 57 |
| Nov 2, 2026 | 57 |
| Nov 1, 2026 | 55 |
| Oct 30, 2026 | 54 |
| Oct 29, 2026 | 59 |
| Oct 28, 2026 | 58 |
| Oct 27, 2026 | 57 |
| Oct 26, 2026 | 57 |
| Oct 25, 2026 | 58 |
| Oct 24, 2026 | 58 |
| Oct 23, 2026 | 59 |
| Oct 22, 2026 | 61 |
| Oct 21, 2026 | 61 |
| Oct 20, 2026 | 62 |
| Oct 19, 2026 | 61 |
| Oct 18, 2026 | 62 |
| Oct 17, 2026 | 62 |
| Oct 16, 2026 | 61 |
| Oct 15, 2026 | 63 |
| Oct 14, 2026 | 63 |
| Oct 13, 2026 | 64 |
| Oct 12, 2026 | 63 |
| Oct 11, 2026 | 62 |
| Oct 10, 2026 | 62 |
| Oct 9, 2026 | 62 |
| Oct 8, 2026 | 60 |
| Oct 7, 2026 | 59 |
| Oct 6, 2026 | 60 |
| Oct 5, 2026 | 61 |
| Oct 4, 2026 | 60 |
| Oct 3, 2026 | 60 |
| Oct 2, 2026 | 60 |
| Oct 1, 2026 | 60 |
| Sep 30, 2026 | 61 |
| Sep 29, 2026 | 61 |
| Sep 28, 2026 | 61 |
| Sep 27, 2026 | 60 |
| Sep 26, 2026 | 60 |
| Sep 25, 2026 | 61 |
| Sep 24, 2026 | 61 |
| Sep 23, 2026 | 62 |
| Sep 22, 2026 | 60 |
| Sep 21, 2026 | 58 |
| Sep 20, 2026 | 57 |
| Sep 19, 2026 | 57 |
| Sep 18, 2026 | 59 |
| Sep 17, 2026 | 58 |
| Sep 16, 2026 | 59 |
| Sep 15, 2026 | 57 |
| Sep 14, 2026 | 58 |
| Sep 13, 2026 | 58 |
| Sep 12, 2026 | 57 |
| Sep 11, 2026 | 58 |
| Sep 10, 2026 | 56 |
| Sep 9, 2026 | 58 |
| Sep 8, 2026 | 59 |
| Sep 7, 2026 | 57 |
| Sep 6, 2026 | 57 |
| Sep 5, 2026 | 57 |
| Sep 4, 2026 | 60 |
| Sep 2, 2026 | 60 |
| Sep 1, 2026 | 60 |
| Aug 31, 2026 | 59 |
| Aug 30, 2026 | 60 |
| Aug 29, 2026 | 59 |
| Aug 28, 2026 | 59 |
| Aug 27, 2026 | 59 |
| Aug 26, 2026 | 58 |
| Aug 25, 2026 | 59 |
| Aug 24, 2026 | 59 |
| Aug 23, 2026 | 60 |
Key facts
- Market cap
- $1.0B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 0.94
- Risk grade (1–10)
- 7
- Next earnings
- Oct 30, 2026
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| NVCR NovoCure | $1.2B | 44 |
| TNDM Tandem Diabetes Care | $1.2B | 38 |
| SIBN SI-BONE | $1.1B | 59 |
| ATEC Alphatec | $1.1B | 52 |
| IART Integra LifeSciences Holdings | $1.1B | 43 |
| CBLL CeriBell | $1.0B | 51 |
Questions
What is IRMD's stock rating today?
IRMD scores 66/100 (Bullish) as of Nov 19, 2026: technical 40, fundamental 72, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does IRADIMED do?
IRADIMED (IRMD) makes medical devices designed to work safely inside MRI suites, where strong magnetic fields rule out most standard equipment. Its main product line is the MRidium family of non-magnetic IV infusion pumps, which let clinicians keep delivering fluids and medications to patients during MRI scans.
Is IRMD stock a buy?
The score is not a buy or sell recommendation. A 66 says the technical and fundamental signals we measure lean bullish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the IRMD score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/irmd/"><img src="https://stocksscores.com/stocks/irmd/badge.svg" alt="IRMD stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/irmd/)